Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses

Blood

Volumn 96, Issue 5, 2000, Pages 1857-1864

  Herr, Wolfgang ^a   Ranieri, Elena ^a   Olson, Walter ^a   Zarour, Hassane ^a   Gesualdo, Loreto ^a   Storkus, Walter J ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 5;

ARTICLE; CANCER IMMUNIZATION; CELL LYSATE; CELL STIMULATION; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 0034283723     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.5.1857.h8001857_1857_1864     Document Type: Article

References (32)

1. Immune intervention against virus-associated human cancers
2. Dendritic ceils and the control of immunity
3. Origin, maturation and antigen-presenting function of dendritic cells
4. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimmulatory dendritic cells under fetal calf serum-free conditions
5. Natural adjuvants: Endogenous activators of dendritic cells
6. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution
7. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
8. Identification of naturally-processed HLA-presented Epstein-Barr virus peptides recognized by ex vivo CD4+ or CD8+ T lymphocytes from human blood
9. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens
10. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
11. A new foreign policy: MHC class I molecules monitor the outside world
12. Murine dendritic cells loaded with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
13. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes
14. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
15. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
16. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses
17. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
18. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
19. Immunization with tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma
20. Human dendritic cells, pulsed with either melanoma tumor ceil lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lyric activity
21. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
22. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
23. Tumor antigens recognized by T cells
24. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
25. Therapeutic vaccination against chronic viral infection: The importance of cooperation between CD4+ and CD8+ T cells
26. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based vaccines
27. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
28. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease
29. Expression of Epstein-Barr virus growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients
30. Epstein-Barr virus
31. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts
32. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease